hydroxyindoleacetic acid has been researched along with Depression, Endogenous in 296 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to investigate the discriminative power of a series of variables (including determination of depressive symptomatology by means of a visual analogue scale, determination of personality traits by means of the Karolinska Scales of Personality, determination of monoamine metabolites in CSF, platelet MAO activities, serum cortisol before and after dexamethasone suppression and urinary melatonin) in differentiating chronic pain patients from healthy subjects, and patients with idiopathic pain syndromes from patients with neurogenic pain syndromes." | 7.67 | Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin. ( Almay, BG; Häggendal, J; Johansson, F; Oreland, L; von Knorring, L; Wetterberg, L, 1986) |
| "Levels of cholecystokinin (CCK) peptides were measured in the CSF from 105 patients suffering from major depressive disorders admitted to a research psychiatric ward for diagnostic evaluation, by a radioimmunoassay method using two different antibodies." | 5.08 | Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. ( Agren, H; Harro, J; Löfberg, C; Oreland, L, 1998) |
| "Sertraline reduced anxiety (p=0." | 3.81 | Long term sertraline effects on neural structures in depressed and nondepressed adult female nonhuman primates. ( Bourland, JD; Clark, A; Daunais, JB; Johnston, WD; Jones, SR; Kraft, RA; Massey, A; Neely, D; Shively, CA; Uberseder, B; Willard, SL; Williamson, JD, 2015) |
| " Thirty-nine depressed inpatients who fulfilled the DSM-IV criteria for major depressive disorder and who did not respond to monotherapy with either imipramine or fluvoxamine participated in this study." | 3.74 | Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration. ( Birkenhäger, TK; Bruijn, JA; Fekkes, D; Moleman, P; Mulder, PG; van den Broek, WW, 2007) |
| " The levels of the urinary main metabolites of norepinephrine 3-methoxy-4-hydroxyphenylglycol (MHPG), of dopamine homovanillic acid (HVA) and of serotonin 5-hydroxyindoleacetic acid (5-HIAA) were measured in 84 patients with major depressive disorder, 34 delusional and 50 nondelusional." | 3.69 | Biogenic amine metabolites in delusional (psychotic) depression and melancholia subtypes of major depression. ( Hatzimanolis, J; Lykouras, L; Malliaras, D; Markianos, M; Stefanis, C, 1994) |
| "Concentrations of cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5-HIAA) were similar in patients with major depressive disorder and in those with non-depressive psychiatric problems, although concentrations were significantly lower in suicidal patients (particularly in those attempters who used violent methods) than in non-suicidal patients." | 3.69 | Prophylactic potential of selective reuptake inhibitors in suicidal patients. ( Banki, CM, 1995) |
| "Performance on tasks tapping automatic and voluntary aspects of memory, attention, and motor speed was examined in 14 patients with major depressive disorder, before and after 3 weeks of treatment with clomipramine (150 mg/day), a potent serotonin and noradrenaline uptake blocker with anticholinergic side effects." | 3.68 | Memory effects of clomipramine treatment: relationship to CSF monoamine metabolites and drug concentrations in plasma. ( Asberg, M; Bartfai, A; Gustavsson, P; Mårtensson, B, 1991) |
| "Lateral ventricle enlargement in schizophrenia has been positively correlated with poor premorbid competence, negative symptoms, and poor treatment response and negatively correlated with concentrations of homovanillic acid (HVA), a dopaminergic metabolite." | 3.68 | Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia. ( Caudle, J; Eccard, M; Jewart, RD; Lewine, RR; Pollard, W; Risby, E; Risch, SC; Stipetic, M, 1991) |
| "In 8 cases of typical neuroleptic malignant syndrome (NMS), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA), noradrenaline (NA), and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) levels in the cerebrospinal fluid (CSF) were assayed during both the active phase of NMS and after recovery." | 3.68 | Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. ( Ishiguro, T; Nisijima, K, 1990) |
| "CSF levels of radioreceptorassayed endorphins Fraction I (EndFI, n = 92) and homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) (n = 118) were measured in patients with major depressive disorders according to Research Diagnostic Criteria (18% were psychotic; 11% hallucinated during the peak of the depressive episode)." | 3.67 | Hallucinations in patients with major depression. Interactions between CSF monoaminergic and endorphinergic indices. ( Agren, H; Terenius, L, 1985) |
| "The effects of electroconvulsive therapy (ECT) on sleep and cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) were studied in 11 male patients suffering from major depressive disorders severe enough to require ECT." | 3.67 | Effects of ECT on sleep and CSF biogenic amines in affective illness. ( Desmedt, D; Hoffmann, G; Kerkhofs, M; Linkowski, P; Mendlewicz, J, 1985) |
| "The aim of the present study was to investigate the discriminative power of a series of variables (including determination of depressive symptomatology by means of a visual analogue scale, determination of personality traits by means of the Karolinska Scales of Personality, determination of monoamine metabolites in CSF, platelet MAO activities, serum cortisol before and after dexamethasone suppression and urinary melatonin) in differentiating chronic pain patients from healthy subjects, and patients with idiopathic pain syndromes from patients with neurogenic pain syndromes." | 3.67 | Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin. ( Almay, BG; Häggendal, J; Johansson, F; Oreland, L; von Knorring, L; Wetterberg, L, 1986) |
| "Patients with idiopathic pain syndromes were compared with healthy volunteers and with patients suffering from chronic pain syndromes of neurogenic origin, with respect to the concentrations of the metabolites 5-hydroxy-indole-acetic acid (5-HIAA) and homovanillic acid (HVA) in cerebrospinal fluid (CSF)." | 3.67 | 5-HIAA and HVA in CSF in patients with idiopathic pain disorders. ( Almay, BG; Häggendal, J; Oreland, L; von Knorring, L, 1987) |
| " Recidivists who committed a new violent offense or arson had significantly lower cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid concentrations and blood glucose nadirs after oral glucose challenge than did nonrecidivists." | 3.67 | Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study. ( Bartko, J; De Jong, J; Goodwin, FK; Linnoila, M; Virkkunen, M, 1989) |
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 3.66 | Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| "Lumbar cerebrospinal fluid levels of 5-hydroxyindoleacetic acid, which are used as indicators of central nervous system serotonergic neuronal activity, were significantly higher in 67 patients with chronic pain and in 32 patients with acute pain (23." | 3.66 | Serotonergic activity in man as a function of pain, pain mechanisms, and depression. ( Duncan, GH; Ghia, JN; Mao, W; Mueller, RA; Scott, DS, 1981) |
| "In the cerebrospinal fluid of 38 patients with major depressive disorders the purine metabolites hypoxanthine and xanthine were positively correlated to the monoamine metabolites HVA and 5HIAA (p less than 0." | 3.66 | Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness? ( Agren, H; Hällgren, R; Niklasson, F, 1983) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the spinal fluid of 45 women hospitalized in a psychiatric department for major depression (14 cases), schizophrenia (18 cases) and alcohol dependence (13 cases)." | 3.66 | Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients. ( Arató, M; Banki, CM, 1983) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the lumbar cerebrospinal fluid of 57 drug-free female patients with DSM-III diagnoses of major unipolar or bipolar depression (n = 14), schizophrenic disorder (n = 18), alcohol dependence (n = 13) and a group of other disorders (n = 12)." | 3.66 | Amine metabolites and neuroendocrine responses related to depression and suicide. ( Arató, M; Banki, CM, 1983) |
| " We hypothesized that selegiline, at a dosage of 60 mg/d, would be at least partially effective but that the higher doses would not maintain the monoamine oxidase B selectivity observed with the lower doses of selegiline." | 2.67 | High-dose selegiline in treatment-resistant older depressive patients. ( Cohen, RM; Lawlor, BA; Mellow, AM; Molchan, S; Mueller, EA; Murphy, DL; Newhouse, PA; Sunderland, T; Tariot, PN, 1994) |
| "Demented patients with Parkinson's disease, particularly those with concurrent depression, had the lowest values of 5-HIAA." | 2.66 | The relationship of serotonin to depression in Parkinson's disease. ( Cote, LJ; Mayeux, R; Sano, M; Stern, Y; Williams, JB, 1988) |
| "Female gender, early age at onset of Parkinson's disease, and greater left brain involvement may also be risk factors." | 2.38 | Depression and Parkinson's disease: a review. ( Cummings, JL, 1992) |
| "Patients with Alzheimer's disease (AD) have been reported to have a rate of nonsuppression on the dexamethasone suppression test (DST) comparable to that of patients with major depression." | 2.38 | The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines. ( Hill, JL; Lawlor, BA; Martinez, R; Mellow, AM; Molchan, SE; Sunderland, T, 1990) |
| " In general, with the possible exception of MAOIs, chronic administration of antidepressants may enhance 5-HT transmission by both pre- and post-synaptic effects, and the relative contributions vary." | 2.37 | Antidepressants and serotonergic neurotransmission: an integrative review. ( Willner, P, 1985) |
| " The dosage of urinary MHPG seems to be a valuable index for the choice of the drug." | 2.36 | [Therapeutic implications of the biochemical features about depressive illness (author's transl)]. ( Lôo, H, 1981) |
| "None of the depressed COPD patients had suicidal ideation." | 1.39 | Positive association between the plasma levels of 5-hydroxyindoleacetic acid and the severity of depression in patients with chronic obstructive pulmonary disease. ( Edakuni, N; Hoshino, T; Imaoka, H; Ito, K; Kawayama, T; Matsunaga, K; Okamoto, M; Sekiduka-Kumano, T; Shoji, Y; Uchimura, N, 2013) |
| "Fluoxetine treatment for 4 and 8 weeks significantly increased basal TPH2 mRNA levels in the midbrain, an effect that was correlated with the appearance of antidepressant-like effects in the forced swim test." | 1.34 | Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect. ( Dygalo, NN; Kalinina, TS; Shishkina, GT, 2007) |
| "Patients with chronic fatigue syndrome showed a significant reduction in basal plasma levels of MHPG and a significant increase in basal plasma levels of 5-HIAA." | 1.28 | Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. ( Dale, JK; Demitrack, MA; Gold, PW; Kling, MA; Krahn, DD; Straus, SE, 1992) |
| "Among 49 consecutive patients with Parkinson's disease, 40% were depressed according to DSM-III; they had major depression or dysthymic disorder accompanied by sleep disturbance, fatigue, psychomotor retardation, loss of self-esteem, and excessive guilt." | 1.27 | Clinical and biochemical features of depression in Parkinson's disease. ( Cote, L; Dyrenfurth, I; Frantz, A; Mayeux, R; Stern, Y; Williams, JB, 1986) |
| "Depression is frequently encountered in Parkinson's disease and was seen to occur in 14 of 26 patients studied." | 1.27 | Depression and Parkinson's disease: possible role of serotonergic mechanisms. ( Bumbasirević, L; Covicković-Sternić, N; Djuricić, BM; Kostić, VS; Mrsulja, BB; Nikolić, M, 1987) |
| "Bilaterally olfactory bulbectomized rats were compared with intact rats in their responsiveness to the acute and chronic administration of nomifensine and trazodone in the learned immobility test of Porsolt." | 1.27 | Effect of bilateral olfactory bulbectomy in the rat, alone or in combination with antidepressants, on the learned immobility model of depression. ( Earley, B; Górka, Z; Leonard, BE, 1985) |
| "Responders with bipolar depression had smaller reductions in MHPG levels than did responders with unipolar depression." | 1.27 | Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. ( Bowden, CL; Davis, JM; Hanin, I; Koslow, SH; Maas, JW; Robins, E, 1985) |
| "Desipramine plasma was much more effective than zimelidine plasma in inhibiting NA uptake in the same preparation." | 1.26 | A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings. ( Aberg-Wistedt, A; Jostell, KG; Ross, SB; Sjöquist, B, 1982) |
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 1.26 | Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 180 (60.81) | 18.7374 |
| 1990's | 76 (25.68) | 18.2507 |
| 2000's | 28 (9.46) | 29.6817 |
| 2010's | 12 (4.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hale, MW | 1 |
| Lukkes, JL | 1 |
| Dady, KF | 1 |
| Kelly, KJ | 1 |
| Paul, ED | 1 |
| Smith, DG | 1 |
| Heinze, JD | 1 |
| Raison, CL | 1 |
| Lowry, CA | 1 |
| Shen, XF | 1 |
| Yuan, HB | 1 |
| Wang, GQ | 1 |
| Xue, H | 1 |
| Liu, YF | 1 |
| Zhang, CX | 1 |
| Ogawa, S | 1 |
| Kunugi, H | 1 |
| Knorr, U | 1 |
| Forman, J | 1 |
| Pech, J | 1 |
| Kessing, LV | 1 |
| Sekiduka-Kumano, T | 1 |
| Kawayama, T | 1 |
| Ito, K | 1 |
| Shoji, Y | 1 |
| Matsunaga, K | 1 |
| Okamoto, M | 1 |
| Edakuni, N | 1 |
| Imaoka, H | 1 |
| Uchimura, N | 1 |
| Hoshino, T | 1 |
| Pudell, C | 1 |
| Vicente, BA | 1 |
| Delattre, AM | 1 |
| Carabelli, B | 1 |
| Mori, MA | 1 |
| Suchecki, D | 1 |
| Machado, RB | 1 |
| Zanata, SM | 1 |
| Visentainer, JV | 1 |
| de Oliveira Santos Junior, O | 1 |
| Lima, MM | 2 |
| Ferraz, AC | 1 |
| Huang, F | 1 |
| Li, J | 1 |
| Shi, HL | 1 |
| Wang, TT | 1 |
| Muhtar, W | 1 |
| Du, M | 1 |
| Zhang, BB | 1 |
| Wu, H | 1 |
| Yang, L | 1 |
| Hu, ZB | 1 |
| Wu, XJ | 1 |
| Santiago, RM | 1 |
| Tonin, FS | 1 |
| Barbiero, J | 1 |
| Zaminelli, T | 1 |
| Boschen, SL | 1 |
| Andreatini, R | 1 |
| Da Cunha, C | 1 |
| Vital, MA | 1 |
| Voget, M | 1 |
| Rummel, J | 1 |
| Avchalumov, Y | 1 |
| Sohr, R | 1 |
| Haumesser, JK | 1 |
| Rea, E | 1 |
| Mathé, AA | 3 |
| Hadar, R | 1 |
| van Riesen, C | 1 |
| Winter, C | 1 |
| Willard, SL | 1 |
| Uberseder, B | 1 |
| Clark, A | 1 |
| Daunais, JB | 1 |
| Johnston, WD | 1 |
| Neely, D | 1 |
| Massey, A | 1 |
| Williamson, JD | 1 |
| Kraft, RA | 1 |
| Bourland, JD | 1 |
| Jones, SR | 1 |
| Shively, CA | 1 |
| Antunes, MS | 1 |
| Ruff, JR | 1 |
| de Oliveira Espinosa, D | 1 |
| Piegas, MB | 1 |
| de Brito, ML | 1 |
| Rocha, KA | 1 |
| de Gomes, MG | 1 |
| Goes, AT | 1 |
| Souza, LC | 1 |
| Donato, F | 1 |
| Boeira, SP | 1 |
| Jesse, CR | 1 |
| Jokinen, J | 5 |
| Nordström, AL | 5 |
| Nordström, P | 7 |
| Majumder, I | 1 |
| White, JM | 1 |
| Irvine, RJ | 1 |
| Heinz, A | 1 |
| Jones, DW | 1 |
| Bissette, G | 3 |
| Hommer, D | 1 |
| Ragan, P | 1 |
| Knable, M | 1 |
| Wellek, S | 1 |
| Linnoila, M | 21 |
| Weinberger, DR | 1 |
| Franke, L | 1 |
| Uebelhack, R | 1 |
| Müller-Oerlinghausen, B | 1 |
| Oquendo, MA | 2 |
| Placidi, GP | 1 |
| Malone, KM | 6 |
| Campbell, C | 1 |
| Keilp, J | 1 |
| Brodsky, B | 1 |
| Kegeles, LS | 1 |
| Cooper, TB | 3 |
| Parsey, RV | 1 |
| van Heertum, RL | 1 |
| Mann, JJ | 12 |
| Urbina, M | 2 |
| Pineda, S | 1 |
| Piñango, L | 1 |
| Carreira, I | 2 |
| Lima, L | 2 |
| Waternaux, C | 1 |
| Haas, GL | 1 |
| Li, S | 2 |
| Westrin, A | 1 |
| Niméus, A | 1 |
| Sher, L | 2 |
| Huang, YY | 1 |
| Grunebaum, MF | 1 |
| Burke, AK | 1 |
| Laine, K | 1 |
| Heikkinen, T | 1 |
| Ekblad, U | 1 |
| Kero, P | 1 |
| Fajardo, O | 1 |
| Galeno, J | 1 |
| Prochazka, H | 1 |
| Agren, H | 16 |
| BURGERMEISTER, JJ | 1 |
| DICK, P | 1 |
| GARONNE, G | 1 |
| GUGGISBERG, M | 1 |
| TISSOT, R | 1 |
| DEGKWITZ, R | 1 |
| SCHULENBURG, O | 1 |
| SIEROSLAWSKI, H | 1 |
| Egashira, N | 1 |
| Iwasaki, K | 1 |
| Takashima, A | 1 |
| Watanabe, T | 1 |
| Kawabe, H | 1 |
| Matsuda, T | 1 |
| Mishima, K | 1 |
| Chidori, S | 1 |
| Nishimura, R | 1 |
| Fujiwara, M | 1 |
| Samuelsson, M | 3 |
| Salomon, RM | 1 |
| Johnson, BW | 1 |
| Schmidt, DE | 1 |
| Arborelius, L | 1 |
| Eklund, MB | 1 |
| Lee, JH | 1 |
| Kim, HJ | 1 |
| Kim, JG | 1 |
| Ryu, V | 1 |
| Kim, BT | 1 |
| Kang, DW | 1 |
| Jahng, JW | 1 |
| Kishida, I | 1 |
| Aklillu, E | 1 |
| Kawanishi, C | 1 |
| Bertilsson, L | 13 |
| Birkenhäger, TK | 1 |
| van den Broek, WW | 1 |
| Fekkes, D | 1 |
| Mulder, PG | 1 |
| Moleman, P | 1 |
| Bruijn, JA | 1 |
| Mårtensson, B | 6 |
| Malkesman, O | 1 |
| Shayit, M | 1 |
| Genud, R | 1 |
| Zangen, A | 1 |
| Kinor, N | 2 |
| Maayan, R | 1 |
| Weizman, A | 1 |
| Weller, A | 2 |
| Yadid, G | 2 |
| Lavi-Avnon, Y | 1 |
| Finberg, JP | 1 |
| Gispan-Herman, I | 1 |
| Stern, Y | 4 |
| Schroeder, M | 1 |
| Gelber, V | 1 |
| Bergman, SY | 1 |
| Overstreet, DH | 1 |
| Shishkina, GT | 1 |
| Kalinina, TS | 1 |
| Dygalo, NN | 1 |
| Kamrowska, A | 1 |
| Bottiglieri, T | 3 |
| Lim, CK | 1 |
| Peters, TJ | 1 |
| Crow, TJ | 1 |
| Cross, AJ | 2 |
| Cooper, SJ | 1 |
| Deakin, JF | 1 |
| Ferrier, IN | 2 |
| Johnson, JA | 1 |
| Joseph, MH | 1 |
| Owen, F | 1 |
| Poulter, M | 1 |
| Lofthouse, R | 1 |
| Morez, VE | 1 |
| Mayeux, R | 4 |
| Rosenthal, NE | 2 |
| Davenport, Y | 1 |
| Cowdry, RW | 3 |
| Webster, MH | 1 |
| Goodwin, FK | 8 |
| Loeb, DC | 1 |
| Roccatagliata, G | 1 |
| Albano, C | 1 |
| Abbruzzese, G | 1 |
| Hollister, LE | 2 |
| Davis, KL | 4 |
| Berger, PA | 6 |
| van Praag, HM | 12 |
| de Haan, S | 2 |
| Träskman-Bendz, L | 14 |
| Asberg, M | 14 |
| Banki, CM | 14 |
| Molnar, G | 5 |
| Fekete, I | 1 |
| Vanderheyden, JE | 2 |
| Noel, G | 2 |
| Mendlewicz, J | 5 |
| Bowden, CL | 9 |
| Redmond, DE | 3 |
| Swann, A | 2 |
| Maas, JW | 13 |
| Stokes, PE | 7 |
| Frazer, A | 2 |
| Casper, R | 3 |
| Träskman, L | 1 |
| Sjöstrand, L | 1 |
| Vojnik, M | 3 |
| Dresse, A | 1 |
| Takahashi, R | 1 |
| Davis, BM | 1 |
| Rothpearl, AB | 2 |
| Faull, KF | 11 |
| Hsieh, JY | 1 |
| Barchas, JD | 5 |
| Nordin, C | 5 |
| Siwers, B | 2 |
| Ghia, JN | 1 |
| Mueller, RA | 1 |
| Duncan, GH | 1 |
| Scott, DS | 1 |
| Mao, W | 1 |
| Lôo, H | 2 |
| Mohs, RC | 1 |
| Lantto, O | 1 |
| Scalia-Tomba, GP | 2 |
| Tybring, G | 2 |
| Johnson, GF | 1 |
| Taylor, MA | 1 |
| Abrams, R | 1 |
| Kocsis, JH | 2 |
| Davis, JM | 11 |
| Hanin, I | 5 |
| Robins, E | 3 |
| Pinder, RM | 2 |
| Stulemeijer, SM | 2 |
| van Dorth, R | 2 |
| Montgomery, SA | 3 |
| Montgomery, DB | 2 |
| Ward, NG | 1 |
| Bloom, VL | 1 |
| Dworkin, S | 1 |
| Fawcett, J | 1 |
| Narasimhachari, N | 1 |
| Friedel, RO | 1 |
| Post, RM | 5 |
| Uhde, TW | 1 |
| Zarifian, E | 1 |
| Aberg-Wistedt, A | 4 |
| Ross, SB | 2 |
| Jostell, KG | 2 |
| Sjöquist, B | 2 |
| Dahl, LE | 1 |
| Lundin, L | 1 |
| le Fèvre Honoré, P | 1 |
| Dencker, SJ | 1 |
| Braithwaite, R | 1 |
| Rydin, E | 1 |
| Schalling, D | 3 |
| Oreland, L | 6 |
| Gerner, RH | 3 |
| Wilkins, JN | 1 |
| Botez, MI | 1 |
| Young, SN | 3 |
| Bachevalier, J | 1 |
| Gauthier, S | 1 |
| Lapierre, YD | 1 |
| Benson, KL | 2 |
| Zarcone, VP | 2 |
| Wide, L | 1 |
| Niklasson, F | 2 |
| Hällgren, R | 1 |
| Mück-Seler, D | 1 |
| Deanović, Z | 1 |
| Jamnicky, B | 1 |
| Jakupcević, M | 1 |
| Mihovilović, M | 1 |
| Korf, J | 1 |
| van den Burg, W | 1 |
| van den Hoofdakker, RH | 1 |
| Strolin Benedetti, M | 1 |
| Arató, M | 7 |
| Karoum, F | 2 |
| Miller, T | 1 |
| Potter, WZ | 8 |
| Osterberg, B | 1 |
| Franzén, O | 1 |
| Papp, Z | 3 |
| Kurcz, M | 1 |
| Kelwala, S | 1 |
| Jones, D | 1 |
| Sitaram, N | 1 |
| Koslow, SH | 9 |
| Javaid, J | 2 |
| Ziporyn, T | 1 |
| Ebert, MH | 3 |
| van Kammen, DP | 1 |
| Plaisant, O | 2 |
| Leboyer, M | 2 |
| Debray, Q | 1 |
| Pelicier, Y | 1 |
| Roy-Byrne, P | 1 |
| Rubinow, DR | 3 |
| Savard, R | 1 |
| Davis, D | 1 |
| Litovitz, G | 1 |
| Scheinin, M | 4 |
| Chang, MD | 1 |
| Cutler, NR | 2 |
| Thorén, P | 2 |
| Miller, TL | 1 |
| Bartko, J | 2 |
| Lieberman, J | 1 |
| Kraemer, GW | 1 |
| Lake, CR | 1 |
| McKinney, WT | 1 |
| Roy, A | 14 |
| Pickar, D | 5 |
| Paul, S | 1 |
| Fink, M | 1 |
| Terenius, L | 2 |
| von Knorring, L | 3 |
| Perris, C | 1 |
| Eisemann, M | 1 |
| Eriksson, U | 1 |
| Perris, H | 1 |
| Jimerson, DC | 1 |
| Katz, MM | 4 |
| Gibbons, RL | 1 |
| Rainer, JD | 1 |
| Cohen, DJ | 2 |
| Fairbanks, L | 2 |
| Anderson, GM | 2 |
| Young, JG | 2 |
| Shaywitz, BA | 2 |
| Hare, TA | 2 |
| Plutchik, R | 2 |
| Faustman, WO | 3 |
| Ringo, DL | 2 |
| Thase, ME | 1 |
| Mieczkowski, T | 2 |
| Myers, JE | 2 |
| Stull, SD | 1 |
| Ortiz, J | 1 |
| Mariscot, C | 1 |
| Alvarez, E | 3 |
| Artigas, F | 4 |
| Wolkowitz, OM | 1 |
| Nemeroff, CB | 3 |
| Greene, KA | 1 |
| Csernansky, JG | 5 |
| Andrianova, EP | 1 |
| Drozdov, AZ | 1 |
| Zhukovskaia, ED | 1 |
| Kukanova, MM | 1 |
| Morozova, GV | 1 |
| Naumovich, AO | 1 |
| Kogan, BM | 1 |
| Lundmark, J | 1 |
| Wålinder, J | 1 |
| Alling, C | 4 |
| Manniche, PM | 1 |
| Dalgaard, L | 1 |
| Sunderland, T | 5 |
| Cohen, RM | 2 |
| Molchan, S | 1 |
| Lawlor, BA | 4 |
| Mellow, AM | 3 |
| Newhouse, PA | 1 |
| Tariot, PN | 2 |
| Mueller, EA | 1 |
| Murphy, DL | 1 |
| Swann, AC | 3 |
| Secunda, SK | 3 |
| Berman, N | 2 |
| Pollack, S | 2 |
| Markianos, M | 4 |
| Alevizos, B | 1 |
| Hatzimanolis, J | 3 |
| Stefanis, C | 4 |
| Kelly, JP | 1 |
| Leonard, BE | 2 |
| Lykouras, L | 2 |
| Malliaras, D | 3 |
| Elliott, PJ | 1 |
| Rudorfer, MV | 6 |
| Skwerer, RG | 1 |
| Radat, F | 2 |
| Morand, P | 1 |
| Nisijima, K | 2 |
| Oyafuso, K | 1 |
| Shimada, T | 1 |
| Hosino, H | 1 |
| Ishiguro, T | 2 |
| Berlin, I | 1 |
| Spreux-Varoquaux, O | 1 |
| Elatki, S | 1 |
| Ferreri, M | 1 |
| Puech, AJ | 1 |
| Sweeney, JA | 1 |
| Brown, RP | 4 |
| Stanley, B | 4 |
| Stanley, M | 5 |
| Sheline, Y | 1 |
| Bardgett, ME | 1 |
| Arranz, B | 1 |
| Blennow, K | 1 |
| Eriksson, A | 1 |
| Månsson, JE | 1 |
| Marcusson, J | 1 |
| Geracioti, TD | 1 |
| Loosen, PT | 1 |
| Ekhator, NN | 1 |
| Schmidt, D | 1 |
| Chambliss, B | 1 |
| Baker, DG | 1 |
| Kasckow, JW | 1 |
| Richtand, NM | 1 |
| Keck, PE | 1 |
| Yoshida, K | 1 |
| Higuchi, H | 1 |
| Kamata, M | 1 |
| Yoshimoto, M | 1 |
| Shimizu, T | 1 |
| Hishikawa, Y | 1 |
| Löfberg, C | 1 |
| Harro, J | 1 |
| Zhou, D | 1 |
| Grecksch, G | 1 |
| Becker, A | 1 |
| Frank, C | 1 |
| Pilz, J | 1 |
| Huether, G | 1 |
| Little, JT | 1 |
| Ketter, TA | 1 |
| Frye, MA | 1 |
| Luckenbaugh, D | 1 |
| Oquendo, M | 1 |
| Underwood, MD | 1 |
| Arango, V | 2 |
| Lambert, G | 1 |
| Johansson, M | 1 |
| Friberg, P | 1 |
| Bäckman, J | 1 |
| Alsén, M | 1 |
| Regnéll, G | 2 |
| Zametkin, AJ | 1 |
| Alter, MR | 1 |
| Yemini, T | 1 |
| Demitrack, MA | 1 |
| Gold, PW | 2 |
| Dale, JK | 1 |
| Krahn, DD | 1 |
| Kling, MA | 1 |
| Straus, SE | 1 |
| Celada, P | 3 |
| Pérez, J | 1 |
| Hyland, K | 1 |
| Laundy, M | 1 |
| Godfrey, P | 1 |
| Carney, MW | 3 |
| Toone, BK | 2 |
| Reynolds, EH | 1 |
| Reddy, PL | 1 |
| Khanna, S | 1 |
| Subhash, MN | 1 |
| Channabasavanna, SM | 2 |
| Rao, BS | 1 |
| Cummings, JL | 1 |
| Virkkunen, M | 3 |
| Vinge, E | 1 |
| Ohman, R | 1 |
| Swedin, A | 1 |
| Zachau, A | 1 |
| McBride, PA | 1 |
| Leon, AC | 1 |
| DeMeo, M | 1 |
| Yamadera, H | 1 |
| Kajimura, N | 1 |
| Kimura, M | 1 |
| Nakamura, S | 1 |
| Suzuki, H | 1 |
| Mori, T | 1 |
| Endo, S | 1 |
| Bryer, JB | 1 |
| Starkstein, SE | 1 |
| Votypka, V | 1 |
| Parikh, RM | 1 |
| Price, TR | 1 |
| Robinson, RG | 1 |
| Linnoila, VM | 1 |
| Dolera, M | 1 |
| Whiteford, HA | 3 |
| Borchert, C | 1 |
| Brown, GL | 3 |
| Linnoila, MI | 1 |
| Maggioni, M | 1 |
| Picotti, GB | 1 |
| Bondiolotti, GP | 1 |
| Panerai, A | 1 |
| Cenacchi, T | 1 |
| Nobile, P | 1 |
| Brambilla, F | 1 |
| Croughan, J | 1 |
| Shirakawa, J | 1 |
| Tanaka, C | 1 |
| Saijoh, K | 1 |
| Gibbons, RD | 3 |
| Hedeker, DR | 1 |
| Jones, JS | 1 |
| Frances, AJ | 1 |
| Guido, JR | 1 |
| Winchel, R | 1 |
| Jibson, M | 1 |
| Przuntek, H | 1 |
| Kuhn, W | 1 |
| Kruesi, MJ | 1 |
| Swedo, S | 1 |
| Leonard, H | 1 |
| Rapoport, JL | 1 |
| DeJong, J | 2 |
| Ravitz, B | 1 |
| Adinoff, B | 2 |
| Risby, ED | 2 |
| Osman, OT | 1 |
| Wägner, A | 1 |
| Beck, O | 1 |
| Brodin, K | 1 |
| Montero, D | 1 |
| Sarrias, MJ | 1 |
| Lester, D | 1 |
| Molchan, SE | 3 |
| Hill, JL | 2 |
| Martinez, R | 1 |
| Martinez, RA | 2 |
| Davis, CL | 1 |
| Lewine, RR | 1 |
| Risch, SC | 2 |
| Risby, E | 1 |
| Stipetic, M | 1 |
| Jewart, RD | 1 |
| Eccard, M | 1 |
| Caudle, J | 1 |
| Pollard, W | 1 |
| Berrettini, WH | 1 |
| Vitiello, B | 1 |
| Engleman, EA | 1 |
| Hingtgen, JN | 1 |
| Zhou, FC | 1 |
| Murphy, JM | 1 |
| Aprison, MH | 1 |
| Ferraro, T | 1 |
| Bartfai, A | 1 |
| Gustavsson, P | 1 |
| Hassanyeh, F | 1 |
| Marshall, EF | 1 |
| Pietraszek, MH | 1 |
| Takahashi, S | 1 |
| Takada, Y | 1 |
| Ohara, K | 2 |
| Inatomi, H | 1 |
| Kondo, N | 1 |
| Takada, A | 1 |
| Ban, TA | 1 |
| Byerley, WF | 1 |
| Mühlbauer, HD | 1 |
| Willner, P | 1 |
| Górka, Z | 1 |
| Earley, B | 1 |
| Wistedt, B | 1 |
| Joyce, PR | 1 |
| Doran, AR | 3 |
| Ninan, P | 1 |
| Paul, SM | 4 |
| Golden, RN | 1 |
| Calil, HM | 1 |
| Ross, RJ | 1 |
| Hendin, H | 1 |
| López-Ibor, JJ | 1 |
| Saiz-Ruiz, J | 1 |
| Pérez de los Cobos, JC | 1 |
| Hoffmann, G | 1 |
| Linkowski, P | 1 |
| Kerkhofs, M | 1 |
| Desmedt, D | 1 |
| Vandel, S | 1 |
| Vandel, B | 1 |
| Bonin, B | 1 |
| Camejo, Z | 1 |
| Sandoz, M | 1 |
| Allers, G | 1 |
| Volmat, R | 1 |
| Hasey, GM | 1 |
| Stancer, HC | 1 |
| Warsh, JJ | 1 |
| Persad, E | 1 |
| Møller, SE | 1 |
| Edman, G | 1 |
| Levander, S | 1 |
| Williams, JB | 3 |
| Cote, L | 2 |
| Frantz, A | 1 |
| Dyrenfurth, I | 1 |
| Standish-Barry, HM | 1 |
| Bouras, N | 1 |
| Hale, AS | 1 |
| Bridges, PK | 1 |
| Bartlett, JR | 1 |
| Edeh, J | 1 |
| Reynolds, EM | 1 |
| Meyendorff, E | 1 |
| Motto, JA | 1 |
| Mefford, IN | 1 |
| Kuniyoshi, M | 1 |
| Nakazawa, Y | 1 |
| Kotorii, T | 1 |
| Almay, BG | 2 |
| Häggendal, J | 2 |
| Johansson, F | 1 |
| Wetterberg, L | 1 |
| Markelova, VF | 1 |
| Belitskaia, RA | 1 |
| Mikhaĭlova, AA | 1 |
| Shumova, OV | 1 |
| Kahn, R | 1 |
| Asnis, GM | 1 |
| Lemus, CZ | 1 |
| Brown, SL | 1 |
| James, D | 1 |
| Sano, M | 2 |
| Koyama, T | 1 |
| Lowy, MT | 1 |
| Meltzer, HY | 1 |
| Kostić, VS | 1 |
| Djuricić, BM | 1 |
| Covicković-Sternić, N | 1 |
| Bumbasirević, L | 1 |
| Nikolić, M | 1 |
| Mrsulja, BB | 1 |
| Conte, H | 1 |
| McKeith, IG | 1 |
| Perry, EK | 1 |
| Candy, JM | 1 |
| Perry, RH | 1 |
| Kilts, CD | 2 |
| Cross, CK | 1 |
| Koslow, S | 1 |
| Everett, D | 1 |
| Bunney, WE | 1 |
| Garland-Bunney, B | 1 |
| Patel, SB | 1 |
| Dent, RR | 1 |
| Ghadirian, AM | 1 |
| Kusalic, M | 1 |
| Peabody, CA | 2 |
| King, RJ | 1 |
| Casper, RC | 1 |
| Stoll, PM | 1 |
| Gjerris, A | 1 |
| Werdelin, L | 1 |
| Gjerris, F | 1 |
| Sørensen, PS | 1 |
| Rafaelsen, OJ | 1 |
| Price, LH | 1 |
| Charney, DS | 1 |
| Heninger, GR | 1 |
| Warner, MD | 1 |
| Hsiao, JK | 2 |
| Bartko, JJ | 1 |
| Timmerman, L | 1 |
| de Beurs, P | 1 |
| Tan, BK | 1 |
| Leijnse-Ybema, H | 1 |
| Sanchez, C | 1 |
| Høpfner Petersen, HE | 1 |
| Cohen Stuart, MH | 1 |
| France, RD | 1 |
| Urban, BJ | 1 |
| Pelton, S | 1 |
| Hong, JS | 1 |
| Lykouras, E | 1 |
| Roehrich, L | 1 |
| Lamparski, D | 1 |
| Custer, R | 1 |
| Lorenz, V | 1 |
| Barbaccia, M | 1 |
| Guidotti, A | 1 |
| Costa, E | 1 |
| Javaid, JI | 1 |
| Chang, SS | 1 |
| Matthews, B | 1 |
| Brown, L | 1 |
| Larsson, M | 1 |
| Forsman, A | 1 |
| Hallgren, J | 1 |
| Pfefferbaum, A | 1 |
| Cote, LJ | 1 |
| Tandon, R | 1 |
| Greden, JF | 1 |
| Kilkowski, J | 1 |
| Anderson, PJ | 1 |
| Kraemer, H | 1 |
| De Leo, D | 1 |
| Marazziti, D | 1 |
| De Jong, J | 2 |
| Nyberg, S | 1 |
| Toresson, G | 1 |
| Brodin, E | 1 |
| Cheetham, SC | 1 |
| Crompton, MR | 1 |
| Czudek, C | 1 |
| Horton, RW | 1 |
| Katona, CL | 1 |
| Reynolds, GP | 1 |
| Balla, KZ | 1 |
| Riederer, P | 1 |
| Beckmann, H | 1 |
| Brücke, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675] | Phase 2 | 80 participants (Actual) | Interventional | 2018-11-26 | Completed | ||
| Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study[NCT02116127] | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| Kinetic Studies in Whole Body and Brain of [11C]DASB PET Imaging of Serotonin Transporters[NCT00059046] | 20 participants | Observational | 2003-04-30 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Neural Correlates of Depressive Symptoms and Reward Related Mechanisms Following AMPT Depletion in Remitted Depressed Patients Off Treatment and Healthy Controls[NCT00082030] | 71 participants (Actual) | Observational | 2004-04-19 | Completed | |||
| Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794] | 61 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study[NCT00086307] | Phase 2 | 39 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported
| Intervention | change in score on a scale (Mean) |
|---|---|
| Placebo | -2.41 |
| Rexulti | -4.88 |
A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
| Intervention | change in score on a scale (Mean) |
|---|---|
| Placebo | -2.09 |
| Rexulti | -3.81 |
A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 76.53 | 68.13 |
| Rexulti | 72.27 | 70.5 |
A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 40.90 | 29.15 |
| Rexulti | 40.54 | 23.15 |
"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 1.15 | 0.23 |
| Rexulti | 0.73 | 0.08 |
A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Major Depressive Episode (Current) | Major Depressive Episode (Past) | Manic Episode (Current) | Manic Episode (Past) | Hypomanic Episode (Current) | Bipolar I Disorder (Current) | Bipolar I Disorder (Past) | Bipolar II Disorder (Current) | Bipolar II Disorder (Past) | Panic Disorder (Current) | Panic Disorder (Lifetime) | Agoraphobia (Current) | Social Anxiety Disorder (Current) | Obsessive Compulsive Disorder (Current) | Post Traumatic Stress Disorder (Current) | Alcohol Use Disorder (Past 12 months) | Substance Use Disorder (Past 12 months) | Any Psychotic Disorder (Current) | Any Psychotic Disorder (Lifetime) | Major Depressive Disorder with Psychotic Features (Current) | Major Depressive Disorder with Psychotic Features (Past) | Anorexia Nervosa (current) | Bulimia Nervosa (Current) | Binge Eating Disorder (Current) | Generalized Anxiety Disorder (Current) | Antisocial Personality Disorder (Lifetime) | ADHD Combined Type (Current) | ADHD Inattentive Type (Current) | ADHD Hyperactive Type (Current) | Tourette's Syndrome (Lifetime) | Persistent Motor Tic Disorder (Lifetime) | Provisional Vocal Tic Disorder (Lifetime) | Provisional Tic Disorder (Lifetime) | Specific Phobia | Body Dysmorphic Disorder (Current) | |
| Placebo | 16 | 12 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 11 | 7 | 6 | 3 | 9 | 13 | 11 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 10 | 8 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 4 | 3 |
| Rexulti | 18 | 18 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 6 | 10 | 9 | 9 | 3 | 12 | 8 | 8 | 0 | 1 | 0 | 0 | 1 | 4 | 4 | 15 | 4 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 |
A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 28.89 | 30.75 |
| Rexulti | 28.70 | 35.71 |
A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 18.2 | 12.8 | 10.7 | 10.7 | 9.7 | 9.6 | 8.7 | 9.3 |
| Rexulti | 17.6 | 10.9 | 7.9 | 8.0 | 7.0 | 6.6 | 6.0 | 5.8 |
Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 17.3 | 13.3 | 11.5 | 12.4 | 11.7 | 11.2 | 12.0 | 12.7 |
| Rexulti | 15.8 | 10.7 | 7.8 | 7.8 | 7.0 | 7.9 | 6.9 | 7.7 |
An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 26.17 | 20.25 |
| Rexulti | 25.42 | 14.21 |
A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 14.9 | 7.6 | 4.7 | 6 | 4.2 | 5.7 | 5 | 8.4 |
| Rexulti | 14.9 | 6.7 | 5.3 | 4.4 | 4.5 | 4.9 | 4 | 3.1 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6
| Intervention | incidents of an adverse event (Number) |
|---|---|
| Double rTMS | 18 |
| M1 Active rTMS + DLPFC Sham rTMS | 14 |
| DLPFC Active rTMS + M1 Sham rTMS | 1 |
| Double Sham rTMS | 1 |
To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 18.7 | 18.1 | 19.0 | 19.3 | 15.8 |
| Double rTMS | 15.6 | 16.2 | 17 | 16.9 | 17.8 |
| Double Sham rTMS | 16.3 | 15.5 | 15.0 | 16.1 | 16.2 |
| M1 Active rTMS + DLPFC Sham rTMS | 15.9 | 16.9 | 14.6 | 15.1 | 12.4 |
To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.7 | 18.2 | 20.2 | 19.0 | 15.7 |
| Double rTMS | 23.2 | 20.7 | 16.4 | 17.9 | 20.1 |
| Double Sham rTMS | 18.8 | 13.7 | 13.1 | 14.7 | 16.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 18.5 | 16.5 | 16.7 | 19.1 | 16.3 |
To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 33.4 | 27.6 | 30.8 | 31.4 | 24.8 |
| Double rTMS | 36.3 | 34.2 | 31.7 | 33.1 | 33.4 |
| Double Sham rTMS | 37.5 | 32.4 | 28.2 | 28.5 | 35.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 34.3 | 31.0 | 30.8 | 27.3 | 28.1 |
To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-Treatment): Severity | Week 1 Post Treatment: Severity | Week 1 Post Treatment: Improvement | Month 1 Post Treatment: Severity | Month 1 Post Treatment: Improvement | Month 3 Post Treatment: Severity | Month 3 Post Treatment: Improvement | Month 6 Post Treatment: Severity | Month 6 Post Treatment: Improvement | |
| DLPFC Active rTMS + M1 Sham rTMS | 4.3 | 4.7 | 3.5 | 4.4 | 3.7 | 4.4 | 3.6 | 4.3 | 3.7 |
| Double rTMS | 4.9 | 4.8 | 3.6 | 4.4 | 3.5 | 4.6 | 3.7 | 4.2 | 3.5 |
| Double Sham rTMS | 3.6 | 3.9 | 3.0 | 4.1 | 3.5 | 4.4 | 3.6 | 4.6 | 3.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 4.7 | 4.9 | 3.5 | 4.8 | 3.8 | 3.8 | 3.4 | 5.0 | 4.2 |
"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 13.8 | 9.4 | 12.4 | 10.4 | 10.4 |
| Double rTMS | 15.2 | 11.3 | 10.6 | 10.7 | 10.4 |
| Double Sham rTMS | 14.1 | 9.3 | 8.0 | 11.1 | 10.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 16.7 | 11.2 | 10.1 | 10.1 | 8.6 |
To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 27.3 | 26.3 | 26.8 | 26.7 | 26.6 |
| Double rTMS | 28.2 | 26.8 | 28.8 | 26.5 | 28.0 |
| Double Sham rTMS | 26.2 | 27.8 | 28.7 | 24.9 | 28.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.6 | 27.1 | 27.2 | 25.3 | 27.9 |
"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 32.8 | 30.3 | 29.3 | 31.5 | 28.8 |
| Double rTMS | 32.3 | 31.2 | 30.1 | 29.6 | 30.5 |
| Double Sham rTMS | 28.9 | 28.2 | 28.6 | 28.6 | 29.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 33.1 | 27.4 | 28.1 | 33.2 | 30.6 |
To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 51.9 | 46.8 | 49.4 | 49.4 | 49 |
| Double rTMS | 57.6 | 51.2 | 49.9 | 51.7 | 50.5 |
| Double Sham rTMS | 55.5 | 43.1 | 40.9 | 43.1 | 47.5 |
| M1 Active rTMS + DLPFC Sham rTMS | 61.5 | 60.7 | 56.8 | 53.1 | 48.3 |
"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.5 | 19.3 | 19.9 | 18.9 | 20.2 |
| Double rTMS | 25.4 | 23.3 | 21.8 | 21.1 | 23.8 |
| Double Sham rTMS | 19.6 | 15.5 | 16.5 | 16.9 | 18.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.1 | 23.2 | 23.0 | 23.2 | 22.7 |
The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 item scale for assessing the severity of depression. Items are rated on a scale of 0 to 6, so the maximum score is 60 and the minimum is 0, where 60 is the most severe depression. Scores of 18 or greater are generally considered to indicate a moderate level of depression. (NCT00086307)
Timeframe: Weekly
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Pramipexole | 22.629 |
| Escitalopram | 26.102 |
| Escitalopram and Pramipexole | 29.455 |
39 reviews available for hydroxyindoleacetic acid and Depression, Endogenous
| Article | Year |
|---|---|
Behavioral manifestations of movement disorders. Parkinson's and Huntington's disease.
Topics: Adult; Aged; Dementia; Depression; Depressive Disorder; Homovanillic Acid; Humans; Huntington Diseas | 1984 |
[Biogenic amines and effective disorders (author's transl)].
Topics: Adult; Biogenic Amines; Brain; Catecholamines; Depressive Disorder; Female; Humans; Hydroxyindoleace | 1981 |
[Therapeutic implications of the biochemical features about depressive illness (author's transl)].
Topics: Antidepressive Agents; Blood Platelets; Brain; Catechol O-Methyltransferase; Depressive Disorder; De | 1981 |
Reassessing the bipolar-unipolar dichotomy.
Topics: Bipolar Disorder; Catechol O-Methyltransferase; Depressive Disorder; Diagnosis, Differential; Female | 1980 |
[Biochemistry of depression and antidepressants].
Topics: Antidepressive Agents; Brain Chemistry; Catechol O-Methyltransferase; Depressive Disorder; Dopamine; | 1982 |
Cerebrospinal fluid probenecid studies: a reinterpretation.
Topics: Biological Transport; Brain; Depressive Disorder; Dopamine; Homovanillic Acid; Humans; Hydroxyindole | 1983 |
[Serotoninergic depression--hypothesis or reality?].
Topics: Blood Platelets; Brain; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Imipramine; Monoamine | 1983 |
Biologic tests in depression.
Topics: Blood Platelets; Depressive Disorder; Dexamethasone; Gonadotropins, Pituitary; Humans; Hydrocortison | 1984 |
The biology of depression: conceptual issues.
Topics: Antidepressive Agents; Body Temperature; Depressive Disorder; Dexamethasone; Humans; Hydrocortisone; | 1984 |
Approaches to neuropeptide and, in particular, endorphin measurements.
Topics: Bipolar Disorder; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Depressive Dis | 1984 |
CSF monoamine metabolites, depression, and suicide.
Topics: Aggression; Analysis of Variance; Biogenic Amines; Depressive Disorder; Dexamethasone; Homicide; Hom | 1984 |
Neurotransmitter hypotheses of depression. Research update.
Topics: Acetylcholine; Depressive Disorder; Dexamethasone; Dopamine; Humans; Hydroxyindoleacetic Acid; Metho | 1984 |
Genetic factors in depression and suicide.
Topics: Adoption; Bipolar Disorder; Depressive Disorder; Diseases in Twins; Electroencephalography; Family; | 1984 |
Recent biologic studies on suicide.
Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Depressive Disorder; Dopamine; Follow-Up Studies; Homovanilli | 1994 |
Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Autoreceptors; Depressive Disorder; Hu | 1996 |
[Prediction of therapeutic response in depressive states].
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1996 |
The neurobiology of suicide risk: a review for the clinician.
Topics: Acting Out; Biomarkers; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Impulsive Behavior; R | 1999 |
Depression and Parkinson's disease: a review.
Topics: Biomarkers; Depressive Disorder; Dopamine; Female; Frontal Lobe; Functional Laterality; Humans; Hydr | 1992 |
Biologic correlates of suicidal risk and aggressive behavioral traits.
Topics: Aggression; Alcoholism; Brain; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Impulsive Beha | 1992 |
Integration of neurobiology and psychopathology in a unified model of suicidal behavior.
Topics: Brain; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Receptors, Serotonin; Risk Factors; Se | 1992 |
Aggression, suicidality, and serotonin.
Topics: Age Factors; Aggression; Alcoholism; Circadian Rhythm; Depressive Disorder; Humans; Hydroxyindoleace | 1992 |
CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence.
Topics: Aggression; Animals; Behavior, Animal; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Impuls | 1990 |
The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines.
Topics: Aged; Alzheimer Disease; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydr | 1990 |
Affective disorders: biological aspects.
Topics: Adrenocorticotropic Hormone; Affective Disorders, Psychotic; Animals; Antidepressive Agents; Brain; | 1985 |
Depression and serotonin metabolism: rationale for neurotransmitter precursor treatment.
Topics: 5-Hydroxytryptophan; Antidepressive Agents, Tricyclic; Blood Platelets; Brain Chemistry; Depressive | 1985 |
Antidepressants and serotonergic neurotransmission: an integrative review.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Depressive Disorder; Disease Models, Animal | 1985 |
Neuroendocrine changes in depression.
Topics: Biogenic Amines; Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydr | 1985 |
Suicide: a review of new directions in research.
Topics: Adolescent; Adult; Aged; Alcoholism; Black or African American; Black People; Delusions; Depressive | 1986 |
Tryptophan to competing amino acids ratio in depressive disorder: relation to efficacy of antidepressive treatments.
Topics: Amino Acids; Amitriptyline; Antidepressive Agents; Brain; Brain Chemistry; Clomipramine; Depressive | 1985 |
Neuropharmacology of S-adenosyl methionine.
Topics: Animals; Antidepressive Agents; Biogenic Amines; Brain; Dementia; Depressive Disorder; Epilepsy; Fol | 1986 |
Affective disorders and aggression disorders: evidence for a common biological mechanism.
Topics: 5-Hydroxytryptophan; Aggression; Blood Platelets; Carrier Proteins; Celiac Disease; Depressive Disor | 1986 |
Human aggression and suicide.
Topics: Adolescent; Adult; Aggression; Animals; Depressive Disorder; Disease Models, Animal; Female; Grief; | 1986 |
Alcoholism and suicide.
Topics: Adult; Age Factors; Alcoholism; Depressive Disorder; Female; Glucose; Homovanillic Acid; Humans; Hyd | 1986 |
Neurochemical findings in suicide completers and suicide attempters.
Topics: Brain Chemistry; Depressive Disorder; Dopamine; Humans; Hydrocortisone; Hydroxyindoleacetic Acid; Im | 1986 |
Clinical considerations of biological correlates of suicide.
Topics: 17-Hydroxycorticosteroids; Antidepressive Agents; Depressive Disorder; Dexamethasone; Electroconvuls | 1986 |
Biological markers in depression.
Topics: Depressive Disorder; Disease Susceptibility; Humans; Hydroxyindoleacetic Acid; Imipramine; Polymorph | 1986 |
Biological prediction of suicide: the role of serotonin.
Topics: Blood Platelets; Carrier Proteins; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Receptors, | 1988 |
The effect on aggression and mood of altering tryptophan levels.
Topics: Affect; Aggression; Amino Acids; Brain; Depressive Disorder; Dietary Proteins; Humans; Hydroxyindole | 1986 |
A clinical perspective on the role of neurotransmitters in mental disorders.
Topics: Antidepressive Agents; Brain Chemistry; Cyclic AMP; Depressive Disorder; Dopamine; Electroconvulsive | 1985 |
22 trials available for hydroxyindoleacetic acid and Depression, Endogenous
| Article | Year |
|---|---|
[3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine.
Topics: Adult; Cell Membrane; Depressive Disorder; Female; Fluoxetine; Humans; Hydroxyindoleacetic Acid; Lym | 1999 |
Self-rated aggression and cerebral monoaminergic turnover. Sex differences in patients with persistent depressive disorder.
Topics: Adult; Aged; Aged, 80 and over; Aggression; Biogenic Monoamines; Brain Chemistry; Depressive Disorde | 2003 |
Central neurochemical ultradian variability in depression.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Female; Homovanillic Acid; Humans; Hyd | 2006 |
Antidepressant effect of femoxetine and desipramine and relationship to the concentration of amine metabolites in cerebrospinal fluid. A double-blind evaluation.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Desipramine; Double-Blind Method; Female; G | 1982 |
Monoamine metabolites in cerebrospinal fluid of depressed patients during treatment with mianserin or amitriptyline.
Topics: Adult; Aged; Amitriptyline; Depressive Disorder; Dibenzazepines; Double-Blind Method; Female; Glycol | 1982 |
Five antidepressant treatments in depressed patients. Effects on urinary serotonin and 5-hydroxyindoleacetic acid output.
Topics: Antidepressive Agents; Clorgyline; Depressive Disorder; Desipramine; Electroconvulsive Therapy; Fema | 1984 |
A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a norepinephrine uptake inhibitor, in endogenous depression: clinical and biochemical findings.
Topics: Adult; Aged; Clinical Trials as Topic; Depressive Disorder; Desipramine; Female; Homovanillic Acid; | 1984 |
Effects of the antidepressant drug tianeptine on plasma and platelet serotonin of depressive patients and healthy controls.
Topics: Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Blood Platelets; Depressive Disorder; Do | 1993 |
The effect of chronic alprazolam on sleep and bioamine metabolites in depression.
Topics: Adult; Alprazolam; Depressive Disorder; Double-Blind Method; Homovanillic Acid; Humans; Hydroxyindol | 1994 |
High-dose selegiline in treatment-resistant older depressive patients.
Topics: Age Factors; Aged; Blood Pressure; Depressive Disorder; Dose-Response Relationship, Drug; Double-Bli | 1994 |
Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients.
Topics: Amitriptyline; Behavior; Bipolar Disorder; Brain Chemistry; Depressive Disorder; Double-Blind Method | 1994 |
Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antidepressive Agents; Benzamides; Biomarkers; Depressive Dis | 1996 |
Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrati | 1997 |
Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour.
Topics: Adult; Aged; Anxiety; Blood Glucose; Cholecystokinin; Depressive Disorder; Female; Homovanillic Acid | 1998 |
Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain; Bupropion; Cross-Over | 1999 |
Effects of phosphatidylserine therapy in geriatric patients with depressive disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Arousal; beta-Endorphin; beta-Lipotropin; C | 1990 |
Stress, depression, and mania: relationship between perceived role of stressful events and clinical and biochemical characteristics.
Topics: Adaptation, Psychological; Adult; Amitriptyline; Arousal; Bipolar Disorder; Catecholamines; Depressi | 1990 |
Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Clorgyline; Depressive Disorder; Desipramine; Female; Gly | 1985 |
Affective illness and S-adenosyl methionine: a preliminary report.
Topics: Adult; Aged; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Folic Acid; | 1986 |
Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects.
Topics: Adult; Aged; Behavior; Blood Pressure; Body Temperature; Depressive Disorder; Desipramine; Drug Resi | 1987 |
A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients.
Topics: Adult; Aged; Anthracenes; Blood Platelets; Citalopram; Clinical Trials as Topic; Depressive Disorder | 1987 |
The relationship of serotonin to depression in Parkinson's disease.
Topics: 5-Hydroxytryptophan; Aged; Clinical Trials as Topic; Dementia; Depressive Disorder; Female; Humans; | 1988 |
235 other studies available for hydroxyindoleacetic acid and Depression, Endogenous
| Article | Year |
|---|---|
Interactions between whole-body heating and citalopram on body temperature, antidepressant-like behaviour, and neurochemistry in adolescent male rats.
Topics: Animals; Antidepressive Agents; Body Temperature; Citalopram; Combined Modality Therapy; Depressive | 2019 |
Role of DNA hypomethylation in lateral habenular nucleus in the development of depressive-like behavior in rats.
Topics: Animals; Decitabine; Depressive Disorder; DNA Methylation; Habenula; Hydroxyindoleacetic Acid; Male; | 2019 |
Evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression.
Topics: Depression; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Neurotransmitt | 2019 |
Low level of evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression compared to healthy non-psychiatric control individuals.
Topics: Depression; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Neurotransmitt | 2019 |
Positive association between the plasma levels of 5-hydroxyindoleacetic acid and the severity of depression in patients with chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 2013 |
Fish oil improves anxiety-like, depressive-like and cognitive behaviors in olfactory bulbectomised rats.
Topics: Animals; Anxiety Disorders; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Cognit | 2014 |
Simultaneous quantification of seven hippocampal neurotransmitters in depression mice by LC-MS/MS.
Topics: Animals; Chromatography, Liquid; Depressive Disorder; Disease Models, Animal; Dopamine; gamma-Aminob | 2014 |
The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.
Topics: Anhedonia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Depressive Disor | 2015 |
Altered local field potential activity and serotonergic neurotransmission are further characteristics of the Flinders sensitive line rat model of depression.
Topics: Alpha Rhythm; Animals; Beta Rhythm; Brain; Depressive Disorder; Disease Models, Animal; Electrodes, | 2015 |
Long term sertraline effects on neural structures in depressed and nondepressed adult female nonhuman primates.
Topics: Administration, Oral; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain; Depressive D | 2015 |
Neuropeptide Y administration reverses tricyclic antidepressant treatment-resistant depression induced by ACTH in mice.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents, Tricyclic; Corticosterone; Depressive D | 2015 |
Cerebrospinal fluid monoamine metabolites and suicide.
Topics: Adult; Aggression; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Intenti | 2009 |
Antidepressant-like effects of 3,4-methylenedioxymethamphetamine in an animal model of depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Central Nervous System Stimulan | 2011 |
Relationship between cortisol and serotonin metabolites and transporters in alcoholism [correction of alcolholism].
Topics: Adult; Affect; Alcoholism; Carrier Proteins; Case-Control Studies; Corticotropin-Releasing Hormone; | 2002 |
Low CSF 5-HIAA level in high-lethality suicide attempters: fact or artifact?
Topics: Aggression; Artifacts; Data Interpretation, Statistical; Depressive Disorder; Humans; Hydroxyindolea | 2002 |
Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression.
Topics: Adult; Age Factors; Brain; Depressive Disorder; Female; Fenfluramine; Fluorodeoxyglucose F18; Glucos | 2003 |
Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders.
Topics: Adolescent; Adult; Aged; Comorbidity; Depressive Disorder; Female; Fenfluramine; Humans; Hydrocortis | 2003 |
The dexamethasone suppression test and CSF-5-HIAA in relation to suicidality and depression in suicide attempters.
Topics: Adult; Depressive Disorder; Dexamethasone; Female; Humans; Hydrocortisone; Hydroxyindoleacetic Acid; | 2003 |
Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism.
Topics: Adult; Alcoholism; Case-Control Studies; Chi-Square Distribution; Chromatography, High Pressure Liqu | 2003 |
Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.
Topics: Adult; Depressive Disorder; Female; Fetal Blood; Humans; Hydroxyindoleacetic Acid; Infant, Newborn; | 2003 |
Serotonin, serotonin 5-HT(1A) receptors and dopamine in blood peripheral lymphocytes of major depression patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Adolescent; Adult; Chromatog | 2003 |
[Urinary excretion of 5-hydroxyindolacetic acid (5-HIAA) in 150 patients with depressive syndrome and maniacal agitation. (Its modifications by 5-hydroxy-tryptophan loading and therapy in the depressive states)].
Topics: Bipolar Disorder; Depression; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Indoleacetic Ac | 1963 |
[THE 5 HIAA EXCRETION IN URINE IN SLEEP AND WAKING].
Topics: Depression; Depressive Disorder; Hydroxyindoleacetic Acid; Indoleacetic Acids; Metabolism; Serotonin | 1964 |
Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain Chemistry; Depressive Disorder; Disease Models, | 2005 |
CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters.
Topics: Adult; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Humans; Hydroxyin | 2006 |
Both long and brief maternal separation produces persistent changes in tissue levels of brain monoamines in middle-aged female rats.
Topics: Aging; Animals; Biogenic Monoamines; Brain; Depressive Disorder; Dopamine; Down-Regulation; Female; | 2007 |
Depressive behaviors and decreased expression of serotonin reuptake transporter in rats that experienced neonatal maternal separation.
Topics: Animals; Animals, Newborn; Anxiety Disorders; Behavior, Animal; Brain; Depressive Disorder; Down-Reg | 2007 |
Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression.
Topics: Adult; Aged; Biogenic Monoamines; Brain Chemistry; Depressive Disorder; DNA Mutational Analysis; Dru | 2007 |
The relationship between CSF HVA/5-HIAA ratio and suicide intent in suicide attempters.
Topics: Adult; Biomarkers; Case-Control Studies; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindo | 2007 |
Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepres | 2007 |
CSF 5-HIAA and DST non-suppression -independent biomarkers in suicide attempters?
Topics: Adult; Biomarkers; Depressive Disorder; Dexamethasone; Female; Glucocorticoids; Humans; Hydrocortiso | 2008 |
Cerebrospinal fluid monoamine metabolites and suicide.
Topics: Biomarkers; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Predictive Val | 2007 |
Dehydroepiandrosterone in the nucleus accumbens is associated with early onset of depressive-behavior: a study in an animal model of childhood depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Animals; Biogenic Monoamines; Child; Dehydroepiandrost | 2007 |
The reward system and maternal behavior in an animal model of depression: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Animals, Newborn; Behavior, Animal; Body Weigh | 2008 |
Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Depressive Disorder; Drug Administration S | 2007 |
[Association between the TPH2 gene and suicidal behavior].
Topics: Alleles; Behavior; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Polymorphism, Genetic; Sui | 2007 |
HPT axis, CSF monoamine metabolites, suicide intent and depression severity in male suicide attempters.
Topics: Adult; Control Groups; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 2008 |
Isocratic analysis of 3-methoxy-4-hydroxyphenyl glycol, 5-hydroxyindole-3-acetic acid and 4-hydroxy-3-methoxyphenylacetic acid in cerebrospinal fluid by high-performance liquid chromatography with amperometric detection.
Topics: Buffers; Chromatography, High Pressure Liquid; Depressive Disorder; Glycols; Homovanillic Acid; Huma | 1984 |
Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides.
Topics: Aged; Aging; Alzheimer Disease; Binding, Competitive; Biogenic Amines; Brain; Choline O-Acetyltransf | 1984 |
[Measurement of aggressiveness by the Gottschalk and Gleser method of verbal sample analysis. Various biochemical and psychodynamic aspects].
Topics: Affect; Aggression; Depressive Disorder; Hostility; Humans; Hydroxyindoleacetic Acid; Personality As | 1984 |
Monoamine metabolites in cerebrospinal fluid of depressive subgroups.
Topics: Adult; Alcoholism; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans | 1980 |
[Cerebrospinal HVA and 5-HIAA in patients with endogenous depression in the course of treatment].
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Bromocriptine; Depressive Disorder; Electroconvulsive | 1980 |
Subtypes of depression based on excretion of MHPG and response to nortriptyline.
Topics: Adult; Depressive Disorder; Glycols; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphenylglycol; M | 1980 |
Chemoprophylaxis of depressions. An attempt to compare lithium with 5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Adult; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Lithium; | 1981 |
Serotonin and noradrenaline uptake inhibitors in the treatment of depression--relationship to 5-HIAA in spinal fluid.
Topics: Antidepressive Agents, Tricyclic; Biogenic Amines; Body Weight; Depressive Disorder; Humans; Hydroxy | 1981 |
Correlation of individual symptoms and other clinical variables with cerebrospinal fluid amine metabolites and tryptophan in depression.
Topics: Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Phenylacetates; Tr | 1981 |
Management of depression with serotonin precursors.
Topics: 5-Hydroxytryptophan; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Hydroxyindoleace | 1981 |
Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method.
Topics: Aged; Dementia; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1981 |
Pretreatment amine neurotransmitter system interrelationships in depression [proceedings].
Topics: Age Factors; Depressive Disorder; Female; Glycols; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhy | 1981 |
Unexpected neuroendocrine-transmitter relationships [proceedings].
Topics: Animals; Circadian Rhythm; Depressive Disorder; Glycols; Humans; Hydrocortisone; Hydroxyindoleacetic | 1981 |
Monoamine metabolites in CSF and suicidal behavior.
Topics: Adult; Age Factors; Aged; Body Height; Depressive Disorder; Female; Follow-Up Studies; Glycols; Homo | 1981 |
Cerebrospinal fluid amine metabolites, tryptophan and clinical parameters in depression. Part 1. Background variables.
Topics: Age Factors; Body Height; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1981 |
Cerebrospinal fluid amine metabolites, tryptophan and clinical parameters in depression. Part 2. Psychopathological symptoms.
Topics: Anxiety; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Phenylace | 1981 |
Cerebrospinal fluid 5-hydroxyindoleacetic acid as an index of central serotonergic processes.
Topics: Adult; Aged; Alcoholism; Brain; Depressive Disorder; Epilepsy; Female; Humans; Hydroxyindoleacetic A | 1981 |
The influence of age, height, and body weight on cerebrospinal fluid amine metabolites and tryptophan in women.
Topics: Adult; Age Factors; Alcoholism; Body Height; Body Weight; Depressive Disorder; Female; Homovanillic | 1981 |
[Monoaminergic hypothesis of depression and classification of antidepressants].
Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; N | 1981 |
Neuroendocrine and neurochemical measurements in depression.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Dexamethasone; Glycols; Homovanillic Acid; Human | 1981 |
Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: I. General patterns.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans; Hydr | 1980 |
Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: II. Suicide.
Topics: Adult; Aged; Anger; Bipolar Disorder; Depressive Disorder; Female; Glycols; Humans; Hydroxyindoleace | 1980 |
Bromocriptine treatment of depressive disorders. Clinical and biochemical effects.
Topics: Adult; Aged; Bromocriptine; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleace | 1981 |
Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism.
Topics: Brain; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 1981 |
Serotonergic activity in man as a function of pain, pain mechanisms, and depression.
Topics: Adult; Chronic Disease; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle | 1981 |
Statistical power in biological psychiatry.
Topics: Depressive Disorder; Dexamethasone; Homovanillic Acid; Humans; Hydrocortisone; Hydroxyindoleacetic A | 1981 |
Gradients of monoamine metabolites and cortisol in cerebrospinal fluid of psychiatric patients and healthy controls.
Topics: Body Height; Depressive Disorder; Glycols; Homovanillic Acid; Humans; Hydrocortisone; Hydroxyindolea | 1982 |
Recent advances in psychopharmacology of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder; Dexa | 1981 |
Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment.
Topics: Amitriptyline; Depressive Disorder; Drug Evaluation; Female; Homovanillic Acid; Humans; Hydroxyindol | 1982 |
CSF monoamine metabolites during treatment with mianserin or amitryptyline.
Topics: Adult; Aged; Amitriptyline; Biogenic Amines; Depressive Disorder; Dibenzazepines; Female; Homovanill | 1982 |
Drug treatment of suicidal behaviour.
Topics: Antidepressive Agents; Brain Chemistry; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindol | 1982 |
Psychobiological markers in coexisting pain and depression: toward a unified theory.
Topics: Anxiety Disorders; Brain; Depressive Disorder; Doxepin; Humans; Hydroxyindoleacetic Acid; Methoxyhyd | 1982 |
Biochemical and psychopathological predictors of suicidality.
Topics: Alcoholism; Brain; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Monoamine Oxidase; Recepto | 1982 |
Biological relationships between mania and melancholia.
Topics: Affective Disorders, Psychotic; Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; D | 1982 |
[Critical view of biochemical factors in depressive syndromes and the prescription of antidepressants].
Topics: Antidepressive Agents; Brain; Catechol O-Methyltransferase; Depressive Disorder; Humans; Hydroxyindo | 1982 |
A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings.
Topics: Adult; Aged; Animals; Antidepressive Agents; Blood Platelets; Brompheniramine; Depressive Disorder; | 1982 |
Urinary excretion of 5-hydroxyindoleacetic acid--no relationship to the level in cerebrospinal fluid.
Topics: Clomipramine; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Suicide, Attempted | 1982 |
Rorschach ratings in depressed and suicidal patients with low levels of 5-hydroxyindoleacetic acid in cerebrospinal fluid.
Topics: Adult; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Personality | 1982 |
Early morning awakening in unipolar depressives with higher levels of platelet MAO activity.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Blood Platelets; Depressive Disorder; Female; Homovanilli | 1982 |
CSF cortisol in patients with depression, mania, or anorexia nervosa and in normal subjects.
Topics: Adult; Affective Disorders, Psychotic; Anorexia Nervosa; Bipolar Disorder; Depressive Disorder; Fema | 1983 |
Effect of folic acid and vitamin B12 deficiencies on 5-hydroxyindoleacetic acid in human cerebrospinal fluid.
Topics: Adolescent; Adult; Aged; Depressive Disorder; Female; Folic Acid; Folic Acid Deficiency; Humans; Hyd | 1982 |
Depression, suicide and the metabolism of serotonin in the brain.
Topics: Brain; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Serotonin; Suicide; Suicide, Attempted | 1982 |
Neurotransmitter functions in depression.
Topics: Catechol O-Methyltransferase; Depressive Disorder; gamma-Aminobutyric Acid; Homovanillic Acid; Human | 1982 |
REM sleep eye movement activity and CSF concentrations of 5-hydroxyindoleacetic acid in psychiatric patients.
Topics: Adult; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Probenecid; Psychot | 1983 |
Patterns of depression reflected in pituitary - thyroid and pituitary - adrenal endocrine changes.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depressive Disorder; Dexamethasone; Homovanillic Acid; Hu | 1982 |
Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness?
Topics: Adult; Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Hypox | 1983 |
Maprotiline in the treatment of endogenous depression: comparison of therapeutic effect with serotonin level in blood platelets.
Topics: Adult; Aged; Animals; Anthracenes; Blood Platelets; Depressive Disorder; Female; Humans; Hydroxyindo | 1983 |
Acid metabolites and precursor amino acids of 5-hydroxytryptamine and dopamine in affective and other psychiatric disorders.
Topics: Adjustment Disorders; Adult; Aged; Amino Acids; Bipolar Disorder; Depressive Disorder; Dopamine; Fem | 1983 |
Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients.
Topics: Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; | 1983 |
5-hydroxytryptamine and depression: a model for the interaction of normal variance with pathology.
Topics: Aggression; Animals; Autopsy; Biogenic Amines; Depressive Disorder; Humans; Hydroxyindoleacetic Acid | 1983 |
Reliability of urinary monoamine and metabolite output measurements in depressed patients.
Topics: Depressive Disorder; Dopamine; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; | 1983 |
Depression and somatosensory evoked potentials: I. Correlations between SEP and monoamine and purine metabolites in CSF.
Topics: Adult; Depressive Disorder; Evoked Potentials, Somatosensory; Female; Fingers; Glycols; Homovanillic | 1983 |
Amine metabolites and neuroendocrine responses related to depression and suicide.
Topics: Alcoholism; Depression; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydro | 1983 |
The effect of dexamethasone on cerebrospinal fluid monoamine metabolites and cortisol in psychiatric patients.
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1983 |
Monoamine metabolites as predictors of antidepressant response: a critique.
Topics: Antidepressive Agents; Brain; Depressive Disorder; Dopamine beta-Hydroxylase; Homovanillic Acid; Hum | 1983 |
CSF 5-HIAA and family history of psychiatric disorder.
Topics: Child, Preschool; Depressive Disorder; Enuresis; Humans; Hydroxyindoleacetic Acid; Mental Disorders | 1983 |
CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis.
Topics: Adult; Affective Disorders, Psychotic; Biogenic Amines; Bipolar Disorder; Depressive Disorder; Epine | 1983 |
Cerebrospinal fluid biochemical examinations: do they reflect clinical or biological differences?
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Calcium; Depressive Disorder; Dexamethasone; Female; Homo | 1983 |
Depression, violent suicide tied to low metabolite level.
Topics: Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Suicide Prevention; Suicide, Attempted | 1983 |
[The concept of serotonergic depression].
Topics: Blood Platelets; Carrier Proteins; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Monoamine | 1983 |
Amine metabolites, neuroendocrine findings, and personality dimensions as correlates of suicidal behavior.
Topics: Adult; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydrocortisone; Hydrox | 1983 |
CSF 5HIAA and personal and family history of suicide in affectively ill patients: a negative study.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; | 1983 |
Effects of electroconvulsive treatment on monoamine metabolites, growth hormone, and prolactin in plasma.
Topics: Adult; Aged; Depressive Disorder; Electroconvulsive Therapy; Female; Growth Hormone; Homovanillic Ac | 1984 |
CSF monoamine metabolites in melancholia.
Topics: Adult; Age Factors; Aged; Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; | 1984 |
Life at risk: markers of suicidality in depression.
Topics: Adult; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydrocortisone; Hydrox | 1983 |
CSF monoamine metabolites of depressed patients during illness and after recovery.
Topics: Adult; Depressive Disorder; Female; Follow-Up Studies; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1984 |
Evidence for a biological hypothesis of obsessive-compulsive disorder.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Depressive Disorder; Dexamethasone; Diseases in Twins; | 1984 |
Cerebrospinal fluid measures of neurotransmitter changes associated with pharmacological alteration of the despair response to social separation in rhesus monkeys.
Topics: alpha-Methyltyrosine; Animals; Anxiety, Separation; Behavior, Animal; Depressive Disorder; Disease M | 1984 |
Some clinical and biochemical predictors of outcome in depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid | 1984 |
Neuroendocrine aspects of the relief of melancholia by induced seizures (electroconvulsive treatment).
Topics: Biogenic Amines; Brain; Catatonia; Cushing Syndrome; Depressive Disorder; Electroconvulsive Therapy; | 1984 |
Pain as a symptom in depressive disorders and its relationship to platelet monoamine oxidase activity.
Topics: Adult; Bipolar Disorder; Blood Platelets; Depressive Disorder; Female; Humans; Hydroxyindoleacetic A | 1984 |
Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder; Female; Homo | 1984 |
CSF neurochemistry of women with anorexia nervosa and normal women.
Topics: Adolescent; Adult; Anorexia Nervosa; Body Weight; Calcium; Choline; Depressive Disorder; Female; gam | 1984 |
Depression type and depression severity in relation to risk of violent suicide attempt.
Topics: Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Risk; Suicide, Attempted; Violence | 1984 |
CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.
Topics: Adolescent; Adult; Age Factors; Aged; Bipolar Disorder; Calcium; Choline; Depressive Disorder; Femal | 1984 |
An association between low levels of 5-HIAA and HVA in cerebrospinal fluid and early mortality in a diagnostically mixed psychiatric sample.
Topics: Adult; Aged; Cause of Death; Depressive Disorder; Follow-Up Studies; Homovanillic Acid; Hospital Rec | 1993 |
Fenfluramine challenge test as a predictor of outcome in major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depressive Disorder; Female; Fenfluramine; Humans; Hydro | 1993 |
Differences in CSF concentrations of thyrotropin-releasing hormone in depressed patients and normal subjects: negative findings.
Topics: Adult; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglyc | 1994 |
CSF 5-HIAA predicts suicide risk after attempted suicide.
Topics: Adult; Aged; Anxiety Disorders; Bipolar Disorder; Cause of Death; Depressive Disorder; Female; Follo | 1994 |
[Various components of the serotonin system in depressive disorders in psychopathic personalities].
Topics: Adolescent; Adult; Antisocial Personality Disorder; Blood Platelets; Depressive Disorder; Humans; Hy | 1994 |
The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients.
Topics: Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methox | 1994 |
5-HT-related, anxiety- and/or aggression-driven depression.
Topics: Aggression; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Humans; Hydroxyindoleacet | 1994 |
Depressive mania versus agitated depression: biogenic amine and hypothalamic-pituitary-adrenocortical function.
Topics: Adult; Aged; Biogenic Amines; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; | 1994 |
Are cerebrospinal fluid or urinary monoamine metabolite measures stronger correlates of suicidal behavior in depression?
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Depressive Disorder; Dopamine; Female; Homovanillic Aci | 1994 |
Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
Topics: Adult; Arousal; Benzamides; Biogenic Amines; Bipolar Disorder; Chromatography, High Pressure Liquid; | 1994 |
The effect of tianeptine and sertraline in three animal models of depression.
Topics: 1-Naphthylamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Antidepress | 1994 |
Biogenic amine metabolites in delusional (psychotic) depression and melancholia subtypes of major depression.
Topics: Biogenic Amines; Delusions; Depressive Disorder; Diagnosis, Differential; Dopamine; Female; Homovani | 1994 |
Prophylactic potential of selective reuptake inhibitors in suicidal patients.
Topics: Binding Sites; Depressive Disorder; Fluvoxamine; Frontal Lobe; Humans; Hydroxyindoleacetic Acid; Imi | 1995 |
CSF 5-HIAA and atmospheric pressure: failure to replicate.
Topics: Atmospheric Pressure; Body Height; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacet | 1993 |
Biogenic amines in seasonal affective disorder: effects of light therapy.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1993 |
Association of biogenic amine metabolites with symptomatology in delusional (psychotic) and nondelusional depressed patients.
Topics: Adult; Biogenic Amines; Delusions; Depressive Disorder; Dopamine; Female; Humans; Hydroxyindoleaceti | 1995 |
Cerebrospinal fluid monoamine metabolism in a case of neuroleptic malignant syndrome improved by electroconvulsive therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Electroconvulsive Therapy; Female; | 1996 |
Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed inpatients.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Depressive Disorder; Female; Homovanillic Acid; H | 1996 |
Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients.
Topics: Adult; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Metho | 1997 |
Serotonergic, noradrenergic, and dopaminergic measures in suicide brains.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Adult; Brain; Depressive Disorder; Dopamine; Fe | 1997 |
Uncoupling of serotonergic and noradrenergic systems in depression: preliminary evidence from continuous cerebrospinal fluid sampling.
Topics: Adult; Analysis of Variance; Biogenic Monoamines; Depressive Disorder; Female; Humans; Hydroxyindole | 1997 |
Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Depressive Disorder; Dopamine; Electric Stimulation; Electr | 1998 |
Serotonergic hyperinnervation of the frontal cortex in an animal model of depression, the bulbectomized rat.
Topics: Animals; Apoenzymes; Binding Sites; Brain Chemistry; Carrier Proteins; Cerebral Cortex; Chromatograp | 1998 |
Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders.
Topics: Adult; Brain; Brain Chemistry; Calorimetry, Indirect; Carbon Dioxide; Carrier Proteins; Catecholamin | 2000 |
Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Dysthymic Disorder; Female; Homovanillic Acid; Hu | 2000 |
Suicide in teenagers: assessment, management, and prevention.
Topics: Adolescent; Adolescent Behavior; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Femal | 2001 |
Central serotonin metabolism and frequency of depression.
Topics: Adult; Bipolar Disorder; Brain; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; | 1979 |
Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings.
Topics: Adult; Anxiety Disorders; Blood-Brain Barrier; Cohort Studies; Depressive Disorder; Fatigue Syndrome | 1992 |
Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
Topics: Adult; Ambulatory Care; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle | 1992 |
Folate deficiency, biopterin and monoamine metabolism in depression.
Topics: Adult; Aged; Biogenic Monoamines; Biopterins; Cerebrospinal Fluid; Depressive Disorder; Female; Homo | 1992 |
CSF amine metabolites in depression.
Topics: Adult; Chromatography, High Pressure Liquid; Depressive Disorder; Female; Homovanillic Acid; Humans; | 1992 |
Prediction of suicidal behavior from biologic tests.
Topics: Aged; Depressive Disorder; Dexamethasone; Epinephrine; Female; Homovanillic Acid; Humans; Hydrocorti | 1992 |
CSF 5-HIAA and atmospheric pressure.
Topics: Adult; Atmospheric Pressure; Body Height; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyind | 1992 |
Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients.
Topics: Adult; Blood Platelets; Depressive Disorder; Female; Fenfluramine; Hospitalization; Humans; Hydroxyi | 1992 |
Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Circadian Rhythm; Depressive Disorder; Dopamine; Female; Foll | 1992 |
The REM rhythm of depression in daytime and sleep EEG.
Topics: Circadian Rhythm; Depressive Disorder; Dexamethasone; Electroencephalography; Female; Homovanillic A | 1992 |
Reduction of CSF monoamine metabolites in poststroke depression: a preliminary report.
Topics: Adult; Aged; Cerebral Infarction; Depressive Disorder; Dominance, Cerebral; Female; Homovanillic Aci | 1992 |
Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement.
Topics: Adult; Blood Platelets; Depressive Disorder; Extracellular Space; Female; Fluvoxamine; Humans; Hydro | 1992 |
Neuroleptic malignant syndrome: a study of CSF monoamine metabolism.
Topics: Adult; Biogenic Monoamines; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid; Humans | 1990 |
CSF 5-HIAA, serum cortisol, and age differentially predict vegetative and cognitive symptoms in depression.
Topics: Adult; Aged; Arousal; Cognition Disorders; Depressive Disorder; Dexamethasone; Female; Humans; Hydro | 1990 |
[5-Hydroxyindole acetic acid assay and the clinical significance].
Topics: Anorexia Nervosa; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Depressive Dis | 1990 |
A comment on the selection of 'healthy controls' for psychiatric experiments.
Topics: Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Mental Disorders; Models, Statistical; Resear | 1990 |
CSF 5-HIAA and HVA concentrations in elderly depressed patients who attempted suicide.
Topics: Age Factors; Aged; Analysis of Variance; Depressive Disorder; Female; Homovanillic Acid; Hospitaliza | 1990 |
Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system.
Topics: Acid-Base Equilibrium; Administration, Oral; Blood-Brain Barrier; Depressive Disorder; Dose-Response | 1990 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
Topics: Carboxy-Lyases; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Le | 1990 |
CSF somatostatin in childhood psychiatric disorders: a preliminary investigation.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Depressi | 1990 |
Cerebrospinal fluid thyrotropin-releasing hormone concentrations in alcoholics and normal controls.
Topics: Adult; Alcoholism; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Hypothalamo-Hypoph | 1990 |
Hypothalamic--pituitary--adrenal axis and monoamine transmitter activity in depression: a pilot study of central and peripheral effects of electroconvulsive therapy.
Topics: Adult; Aged; Catecholamines; Corticotropin-Releasing Hormone; Depressive Disorder; Electroconvulsive | 1991 |
Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder.
Topics: Adult; Blood Platelets; Carrier Proteins; Clomipramine; Depressive Disorder; Female; Homovanillic Ac | 1991 |
Serotonin and 5-hydroxyindoleacetic acid in plasma. Potential use as peripheral measures of MAO-A activity.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Depressive Disorder; Female; Humans; Hydroxyin | 1990 |
Concentrations of cerebrospinal fluid monoamine metabolites in suicides.
Topics: 3,4-Dihydroxyphenylacetic Acid; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1991 |
CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression.
Topics: Aged; Alzheimer Disease; Depressive Disorder; Diagnosis, Differential; Female; Homovanillic Acid; Hu | 1991 |
Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia.
Topics: Adult; Age Factors; Bipolar Disorder; Body Height; Body Weight; Brain; Brain Chemistry; Cerebral Ven | 1991 |
Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Depressive Disorder; Dynorphins; Female; Galanin; Homovanillic Acid; | 1991 |
Potentiated 5-hydroxytryptophan response suppression following 5,7-dihydroxytryptamine raphe lesions in an animal model of depression.
Topics: 5,7-Dihydroxytryptamine; Animals; Arousal; Depressive Disorder; Frontal Lobe; Hydroxyindoleacetic Ac | 1991 |
CSF GABA in depressed patients and normal controls.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Homovanillic Acid; Hu | 1991 |
Memory effects of clomipramine treatment: relationship to CSF monoamine metabolites and drug concentrations in plasma.
Topics: Adult; Aged; Attention; Brain; Clomipramine; Depressive Disorder; Female; Homovanillic Acid; Humans; | 1991 |
Measures of serotonin metabolism in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1991 |
Diurnal patterns of serotonin, 5-hydroxyindoleacetic acid, tryptophan and fibrinolytic activity in blood of depressive patients and healthy volunteers.
Topics: Adult; Circadian Rhythm; Depressive Disorder; Female; Fibrinolysis; Humans; Hydroxyindoleacetic Acid | 1991 |
Hallucinations in patients with major depression. Interactions between CSF monoaminergic and endorphinergic indices.
Topics: Adult; Age Factors; Bipolar Disorder; Depressive Disorder; Endorphins; Female; Hallucinations; Homov | 1985 |
Human aggression and the role of central serotonin.
Topics: Aggression; Brain; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Interpe | 1985 |
Effect of bilateral olfactory bulbectomy in the rat, alone or in combination with antidepressants, on the learned immobility model of depression.
Topics: Amygdala; Animals; Depressive Disorder; Disease Models, Animal; Humans; Hydroxyindoleacetic Acid; Is | 1985 |
Higher CSF levels of HVA and 5-HIAA in delusional compared to nondelusional depression.
Topics: Adult; Aged; Delusions; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1985 |
Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Bipolar Disorder; Depressive Disorder; Dopamine; Female | 1985 |
Biological correlations of suicide and aggressivity in major depressions (with melancholia): 5-hydroxyindoleacetic acid and cortisol in cerebral spinal fluid, dexamethasone suppression test and therapeutic response to 5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Adult; Aggression; Bipolar Disorder; Carbidopa; Depressive Disorder; Dexamethas | 1985 |
Effects of ECT on sleep and CSF biogenic amines in affective illness.
Topics: Adult; Biogenic Amines; Bipolar Disorder; Depressive Disorder; Electroconvulsive Therapy; Homovanill | 1985 |
Biological markers in depression. Monoamine metabolites in urine of depressed patients and normal subjects.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans; Hydro | 1985 |
Neurotransmitter metabolites and endocrine responses in depression.
Topics: Adult; Depressive Disorder; Female; Growth Hormone; Hormones; Humans; Hydroxyindoleacetic Acid; Male | 1985 |
Cerebrospinal fluid monoamine and monoamine metabolite levels and the dexamethasone suppression test in depression. Relationship to life events.
Topics: Adult; Depressive Disorder; Dexamethasone; Dopamine; Female; Humans; Hydrocortisone; Hydroxyindoleac | 1986 |
Skin conductance habituation and cerebrospinal fluid 5-hydroxyindoleacetic acid in suicidal patients.
Topics: Adult; Aged; Animals; Depressive Disorder; Female; Galvanic Skin Response; Guinea Pigs; Habituation, | 1986 |
Clinical and biochemical features of depression in Parkinson's disease.
Topics: Aged; Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydroxyindoleac | 1986 |
Ventricular size and CSF transmitter metabolite concentrations in severe endogenous depression.
Topics: Adult; Aged; Cerebral Ventricles; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Mal | 1986 |
Tricyclic antidepressant washout effects on cerebrospinal fluid and urinary monoamine and metabolites.
Topics: Amines; Antidepressive Agents, Tricyclic; Depressive Disorder; Epinephrine; Homovanillic Acid; Human | 1986 |
Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects.
Topics: Bipolar Disorder; Depressive Disorder; Female; Glycols; Homovanillic Acid; Hospitalization; Humans; | 1986 |
Biological suicide research: outcome and limitations.
Topics: Aggression; Catecholamines; Depressive Disorder; Humans; Hydrocortisone; Hydroxyindoleacetic Acid; M | 1986 |
Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels.
Topics: Depressive Disorder; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphe | 1986 |
Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF.
Topics: Adolescent; Adult; Aged; Animals; Brain; Brain Chemistry; Depressive Disorder; Dogs; Dopamine; Femal | 1986 |
Some biological rhythms in a unipolar depression--a preliminary case report.
Topics: Circadian Rhythm; Depressive Disorder; Electrolytes; Humans; Hydrocortisone; Hydroxyindoleacetic Aci | 1986 |
Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression.
Topics: Adult; Aged; Aged, 80 and over; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Human | 1986 |
(Auto)aggression and CSF 5-HIAA in depression and schizophrenia.
Topics: Aggression; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Risk; Schizophrenia; Schizophreni | 1986 |
Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin.
Topics: Adult; Chronic Disease; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydrocortisone; Hydr | 1986 |
[Serotoninergic and catecholaminergic indices in patients with neurotic and depressive disorders and changes in them as a result of reflexotherapy].
Topics: Acupuncture Therapy; Adult; Catecholamines; Depressive Disorder; Dihydroxyphenylalanine; Female; Hum | 1986 |
Therapeutic indications for serotonin-potentiating compounds: a hypothesis.
Topics: 5-Hydroxytryptophan; Aggression; Antidepressive Agents; Anxiety; Brain; Depressive Disorder; Desipra | 1987 |
Pharmacological specificity is not the same as clinical selectivity.
Topics: Depressive Disorder; Double-Blind Method; Humans; Hydroxyindoleacetic Acid; Maprotiline; Methoxyhydr | 1987 |
Depression and Parkinson's disease.
Topics: Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydrocortisone; Hydro | 1987 |
5-Hydroxytryptophan-induced cortisol response and CSF 5-HIAA in depressed patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Adult; Brain; Depressive Disorder; Female; Homo | 1987 |
Depression and Parkinson's disease: possible role of serotonergic mechanisms.
Topics: Aged; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Parkinson Di | 1987 |
The serotonin hypothesis of (auto)aggression. Critical appraisal of the evidence.
Topics: Aggression; Brain; Depressive Disorder; Hostility; Humans; Hydroxyindoleacetic Acid; Lesch-Nyhan Syn | 1986 |
Postmortem neurochemical studies in depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Brain; Carrier Proteins; Depressive Disorder; Electr | 1986 |
Serotonergic function and suicidal behavior in personality disorders.
Topics: Brain; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Personality Disorders; Risk; Schizophr | 1986 |
Cerebrospinal fluid correlates of suicide attempts and aggression.
Topics: Aggression; Animals; Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindole | 1986 |
Aminergic studies and cerebrospinal fluid cations in suicide.
Topics: Adult; Aged; Calcium; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1986 |
Studies of amine metabolites in depressed patients. Relationship to suicidal behavior.
Topics: Bipolar Disorder; Brain; Depressive Disorder; Epinephrine; Homovanillic Acid; Humans; Hydrocortisone | 1986 |
Cerebrospinal fluid studies in suicide. An overview.
Topics: Aggression; Brain; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxy | 1986 |
Suicide, aggression, and depression. A theoretical framework for future research.
Topics: Adoption; Aggression; Brain; Depressive Disorder; Humans; Hydroxyindoleacetic Acid; Risk; Seasons; S | 1986 |
Platelet tritiated imipramine binding and serotonin uptake in depressed patients and controls. Relationship to plasma cortisol levels before and after dexamethasone administration.
Topics: Adult; Blood Platelets; Carrier Proteins; Depressive Disorder; Dexamethasone; Female; Homovanillic A | 1987 |
5-HIAA and HVA in CSF in patients with idiopathic pain disorders.
Topics: Adult; Age Factors; Aged; Body Weight; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydro | 1987 |
Diurnal rhythms of plasma cortisol, beta-endorphin and prolactin, and cerebrospinal fluid amine metabolite levels before suicide. Case report.
Topics: beta-Endorphin; Catecholamines; Circadian Rhythm; Depressive Disorder; Endorphins; Homovanillic Acid | 1986 |
Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline.
Topics: Administration, Oral; Adult; Aged; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Ma | 1987 |
CSF amine metabolites and depression.
Topics: Adult; Aged; Depressive Disorder; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male | 1987 |
Biogenic amine and metabolite levels in depressed patients with high versus normal hypothalamic-pituitary-adrenocortical activity.
Topics: Biogenic Amines; Depressive Disorder; Dexamethasone; Epinephrine; Homovanillic Acid; Humans; Hydroco | 1987 |
CSF-amine metabolites in depression, dementia and in controls.
Topics: Biogenic Amines; Body Height; Dementia; Depressive Disorder; Homovanillic Acid; Humans; Hydrocephalu | 1987 |
TRH stimulation test and depression.
Topics: Adult; Aged; Depressive Disorder; Dexamethasone; Homovanillic Acid; Humans; Hydrocortisone; Hydroxyi | 1987 |
The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio.
Topics: Alzheimer Disease; Antidepressive Agents; Cerebrospinal Fluid; Depressive Disorder; Drug Evaluation; | 1987 |
Monoamine neurotransmitter interactions and the prediction of antidepressant response.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Glycols; Homovanillic Acid; Humans; Hydro | 1987 |
CSF monoamine metabolites in chronic pain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Back Pain; Biogenic Amines; Chronic Disease; Depressive | 1987 |
Neurochemical variables in delusional depression.
Topics: Adult; Blood Platelets; Cyclic AMP; Delusions; Depressive Disorder; Dopamine; Dopamine beta-Hydroxyl | 1988 |
Pathological gambling. A psychobiological study.
Topics: Adult; Brain; Corticotropin-Releasing Hormone; Depressive Disorder; Disruptive, Impulse Control, and | 1988 |
Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls.
Topics: Biogenic Amines; Circadian Rhythm; Depressive Disorder; Epinephrine; Female; Homovanillic Acid; Huma | 1988 |
N-acetylation and serotonergic measures in a group of psychiatric patients.
Topics: Acetylation; Adult; Bipolar Disorder; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; | 1988 |
HPLC assays of 5-HIAA and tryptophan in cerebrospinal fluid and 5-HT and tryptophan in blood: a methodological study with clinical applications.
Topics: Adult; Aging; Antidepressive Agents, Tricyclic; Blood Platelets; Chromatography, High Pressure Liqui | 1988 |
Seasonal changes of CSF monoamine metabolites in psychiatric patients: what is the source?
Topics: Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mental D | 1988 |
CSF biochemical correlates of mixed affective states.
Topics: Adult; Bipolar Disorder; Calcium; Depressive Disorder; Electrolytes; Female; Homovanillic Acid; Huma | 1988 |
Corrections to a 1980 article on CSF monoamine metabolites.
Topics: 3,4-Dihydroxyphenylacetic Acid; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1989 |
Relationships between clinical symptoms and monoamine metabolite concentrations in biochemically defined subgroups of depressed patients.
Topics: Depressive Disorder; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphe | 1988 |
The benefits and risks of 5-HT uptake inhibitors in depression.
Topics: Aggression; Depressive Disorder; Female; Fluoxetine; Humans; Hydroxyindoleacetic Acid; Male; Seroton | 1988 |
Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study.
Topics: Adult; Alcoholism; Blood Glucose; Criminal Psychology; Depressive Disorder; Disruptive, Impulse Cont | 1989 |
Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Dopamine; Female; Follow-Up Studies; Homovanillic Acid | 1989 |
Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid.
Topics: Adult; Aged; Depressive Disorder; Female; Fluoxetine; Glycols; Homovanillic Acid; Humans; Hydroxyind | 1989 |
Serotonin concentrations and turnover in brains of depressed suicides.
Topics: Adolescent; Adult; Brain; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; Middl | 1989 |
Cerebrospinal fluid magnesium and calcium related to amine metabolites, diagnosis, and suicide attempts.
Topics: Adjustment Disorders; Adult; Aged; Calcium; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1985 |
Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid.
Topics: Adult; Amitriptyline; Bipolar Disorder; Depressive Disorder; Dopamine; Double-Blind Method; Female; | 1985 |
[Current biochemical hypotheses of endogenous depression].
Topics: 5-Hydroxytryptophan; Amitriptyline; Autopsy; Biogenic Amines; Bipolar Disorder; Brain; Depressive Di | 1985 |